GeneDx Holdings Corp. (NASDAQ:WGS) CFO Sells $12,188.16 in Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 1,104 shares of the firm’s stock in a transaction that occurred on Monday, April 29th. The stock was sold at an average price of $11.04, for a total transaction of $12,188.16. Following the completion of the transaction, the chief financial officer now directly owns 30,836 shares in the company, valued at approximately $340,429.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Kevin Feeley also recently made the following trade(s):

• On Monday, March 18th, Kevin Feeley sold 3,253 shares of GeneDx stock. The shares were sold at an average price of $10.59, for a total transaction of $34,449.27.

GeneDx Stock Performance

Shares of NASDAQ WGS opened at $20.92 on Thursday. The stock has a market cap of $545.05 million, a PE ratio of -4.04 and a beta of 2.75. GeneDx Holdings Corp. has a 1 year low of $1.16 and a 1 year high of $21.49. The firm has a fifty day moving average price of $9.63 and a 200-day moving average price of $5.19. The company has a debt-to-equity ratio of 0.23, a current ratio of 3.10 and a quick ratio of 2.95.

GeneDx (NASDAQ:WGS) last issued its quarterly earnings results on Tuesday, February 20th. The company reported ($0.59) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.01. The business had revenue of $57.42 million during the quarter, compared to analyst estimates of $57.00 million. GeneDx had a negative return on equity of 34.40% and a negative net margin of 60.86%. Equities analysts anticipate that GeneDx Holdings Corp. will post -2.02 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on WGS. BTIG Research boosted their price objective on shares of GeneDx from $15.00 to $19.00 and gave the company a “buy” rating in a research report on Tuesday. The Goldman Sachs Group boosted their price target on GeneDx to $11.00 and gave the company a “neutral” rating in a report on Monday, April 15th. Finally, TD Cowen raised their price objective on GeneDx from $14.00 to $24.00 and gave the stock a “buy” rating in a research note on Tuesday.

Institutional Trading of GeneDx

Institutional investors have recently made changes to their positions in the business. Oracle Investment Management Inc. lifted its holdings in GeneDx by 14.9% in the 3rd quarter. Oracle Investment Management Inc. now owns 994,580 shares of the company’s stock worth $3,620,000 after purchasing an additional 128,731 shares in the last quarter. Decheng Capital LLC bought a new stake in shares of GeneDx during the fourth quarter valued at approximately $285,000. Trellus Management Company LLC lifted its holdings in shares of GeneDx by 55.0% in the third quarter. Trellus Management Company LLC now owns 155,012 shares of the company’s stock worth $564,000 after buying an additional 54,976 shares in the last quarter. Pathstone Family Office LLC boosted its position in shares of GeneDx by 262.2% during the third quarter. Pathstone Family Office LLC now owns 54,327 shares of the company’s stock worth $198,000 after acquiring an additional 39,327 shares during the last quarter. Finally, HighTower Advisors LLC grew its stake in GeneDx by 14.1% during the third quarter. HighTower Advisors LLC now owns 237,948 shares of the company’s stock valued at $865,000 after acquiring an additional 29,361 shares in the last quarter. Hedge funds and other institutional investors own 61.72% of the company’s stock.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.